Fred E. Cohen - 29 May 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director, 10%+ Owner
Issuer symbol: KYTX
Report date: 29 May 2025
Net transaction value: $0
Form type: 4
Accepted by SEC: 02 Jun 2025, 18:30:04 UTC
Previous filing: 08 Aug 2024
Next filing: 13 Jun 2025
SEC filing: View on sec.gov
Reporting owner signature: By: /s/ Ryan Jones, as Attorney-in-Fact

Key filing fact

Fred E. Cohen filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 02 Jun 2025.

Key facts

This page summarizes Fred E. Cohen's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2025, 18:30.

Change

Previous filing in this sequence was filed on 08 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001339358 Primary reporting owner

Cohen Fred E

Relationship: Director, 10%+ Owner
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE
Signature: By: /s/ Ryan Jones, as Attorney-in-Fact
Signature date: 02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Award

Transaction value: $0
Shares: +16,634
Change %
Price: $0.000000
Shares after: 16,634
Date: 29 May 2025
Ownership: Direct
Footnotes: F1

KYTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,523,924
Date: 29 May 2025
Ownership: See Footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +65,351
Change %
Price: $0.000000
Shares after: 65,351
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,351
Exercise price: $2.63
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F2

All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F3

Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.